Your browser doesn't support javascript.
loading
Risk Factors for Infections Involving Cardiac Implanted Electronic Devices.
Birnie, David H; Wang, Jia; Alings, Marco; Philippon, François; Parkash, Ratika; Manlucu, Jaimie; Angaran, Paul; Rinne, Claus; Coutu, Benoit; Low, R Aaron; Essebag, Vidal; Morillo, Carlos; Redfearn, Damian; Toal, Satish; Becker, Giuliano; Degrâce, Michel; Thibault, Bernard; Crystal, Eugene; Tung, Stanley; LeMaitre, John; Sultan, Omar; Bennett, Matthew; Bashir, Jamil; Ayala-Paredes, Felix; Gervais, Philippe; Rioux, Leon; Hemels, Martin E W; Bouwels, Leon H R; Exner, Derek V; Dorian, Paul; Connolly, Stuart J; Longtin, Yves; Krahn, Andrew D.
Afiliação
  • Birnie DH; University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
  • Wang J; Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada.
  • Alings M; Amphia Ziekenhuis and Working Group on Cardiovascular Research the Netherlands, Breda, the Netherlands.
  • Philippon F; Institut universitaire de cardiologie et de pneumologie de Québec, Laval University, Quebec City, Quebec, Canada.
  • Parkash R; Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada.
  • Manlucu J; Lawson Health Research Institute, London Health Sciences, Western University, London, Ontario, Canada.
  • Angaran P; Department of Medicine, University of Toronto, Division of Cardiology, St. Michael Hospital, Toronto, Ontario, Canada.
  • Rinne C; St. Mary's General Hospital, Kitchener, Ontario, Canada.
  • Coutu B; Centre hospitalier de l'Université de Montréal, University of Montreal, Montreal, Quebec, Canada.
  • Low RA; Chinook Regional Hospital, Lethbridge, Alberta, Canada.
  • Essebag V; McGill University Health Center, Montreal, Quebec, Canada.
  • Morillo C; Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada.
  • Redfearn D; Kingston General Hospital, Queen's University, Kingston, Ontario, Canada.
  • Toal S; Horizon Health Network, Saint John, New Brunswick, Canada.
  • Becker G; Hôpital du Sacré-Coeur de Montréal, University of Montreal, Montreal, Quebec, Canada.
  • Degrâce M; Hôtel-Dieu de Lévis, Lévis, Quebec, Canada.
  • Thibault B; Montreal Heart Institute, Montreal, Quebec, Canada.
  • Crystal E; Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
  • Tung S; St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
  • LeMaitre J; Royal Columbian Hospital, New Westminster, British Columbia, Canada.
  • Sultan O; Regina General Hospital, Saskatchewan Health Authority, Regina, Saskatchewan, Canada.
  • Bennett M; Regina General Hospital, Saskatchewan Health Authority, Regina, Saskatchewan, Canada; Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
  • Bashir J; University of British Columbia, Vancouver, British Columbia, Canada.
  • Ayala-Paredes F; Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada.
  • Gervais P; Institut universitaire de cardiologie et de pneumologie de Québec, Laval University, Quebec City, Quebec, Canada.
  • Rioux L; Centre de santé et de services sociaux de Rimouski-Neigette, Rimouski, Quebec, Canada.
  • Hemels MEW; Rijnstate Hospital, Arnhem, the Netherlands; Radboud University Medical Centre, Nijmegen, the Netherlands.
  • Bouwels LHR; Canisius Wilhelmina Ziekenhuis, Nijmegen, the Netherlands.
  • Exner DV; Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada.
  • Dorian P; Department of Medicine, University of Toronto, Division of Cardiology, St. Michael Hospital, Toronto, Ontario, Canada.
  • Connolly SJ; Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada.
  • Longtin Y; Jewish General Hospital Sir Mortimer B. Davis, McGill University, Montreal, Quebec, Canada.
  • Krahn AD; University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: akrahn@mail.ubc.ca.
J Am Coll Cardiol ; 74(23): 2845-2854, 2019 12 10.
Article em En | MEDLINE | ID: mdl-31806127
BACKGROUND: Cardiac implantable electronic device infection is a major complication that usually requires device removal. PADIT (Prevention of Arrhythmia Device Infection Trial) was a large cluster crossover trial of conventional versus incremental antibiotics. OBJECTIVES: This study sought to investigate independent predictors of device infection in PADIT and develop a novel infection risk score. METHODS: In brief, over 4 6-month periods, 28 centers used either conventional or incremental prophylactic antibiotic treatment in all patients. The primary outcome was hospitalization for device infection within 1 year (blinded endpoint adjudication). Multivariable logistic prediction modeling was used to identify the independent predictors and develop a risk score for device infection. The prediction models were internally validated with bootstrap methods. RESULTS: Device procedures were performed in 19,603 patients, and hospitalization for infection occurred in 177 (0.90%) within 1 year of follow-up. The final prediction model identified 5 independent predictors of device infection (prior procedures [P], age [A], depressed renal function [D], immunocompromised [I], and procedure type [T]) with an optimism-corrected C-statistic of 0.704 (95% confidence interval: 0.660 to 0.744). A PADIT risk score ranging from 0 to 15 points classified patients into low (0 to 4), intermediate (5 to 6) and high (≥7) risk groups with rates of hospitalization for infection of 0.51%, 1.42%, and 3.41%, respectively. CONCLUSIONS: This study identified 5 independent predictors of device infection and developed a novel infection risk score in the largest cardiac implantable electronic device trial to date, warranting validation in an independent cohort. The 5 independent predictors in the PADIT score are readily adopted into clinical practice. (Prevention of Arrhythmia Device Infection Trial [PADIT Pilot]; NCT01002911).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Marca-Passo Artificial / Infecções Relacionadas à Prótese / Desfibriladores Implantáveis / Medição de Risco / Antibioticoprofilaxia / Hospitalização Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male País/Região como assunto: America do norte Idioma: En Revista: J Am Coll Cardiol Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Marca-Passo Artificial / Infecções Relacionadas à Prótese / Desfibriladores Implantáveis / Medição de Risco / Antibioticoprofilaxia / Hospitalização Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male País/Região como assunto: America do norte Idioma: En Revista: J Am Coll Cardiol Ano de publicação: 2019 Tipo de documento: Article